Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Tryptamine Therapeutics ( (AU:ENP) ) is now available.
Entropy Neurodynamics Limited has applied for quotation on the ASX of 13,823,528 ordinary fully paid shares, to be issued on April 14, 2026 under the code ENP. The application, lodged as a new announcement, formalizes the listing of these securities and increases the company’s freely tradable share base, potentially enhancing liquidity and accessibility for investors.
The move reflects a step in the company’s ongoing capital markets activity, as the securities are being issued in connection with transactions previously signaled to the market. By expanding the pool of quoted shares, Entropy Neurodynamics may improve its market visibility and provide additional avenues for existing and new shareholders to adjust their positions in the stock.
More about Tryptamine Therapeutics
Entropy Neurodynamics Limited is an Australian-listed company trading on the ASX under the ticker ENP. Limited information is provided in the filing about its specific industry focus, products or services, or target markets, beyond its status as a listed corporate entity.
Average Trading Volume: 2,377,684
Technical Sentiment Signal: Sell
Current Market Cap: A$48.52M
See more data about ENP stock on TipRanks’ Stock Analysis page.